Biotinylated Human EMMPRIN / CD147 Protein, Avitag™,His Tag

Proteins and Peptides

貨號 Cat. No.
CD7-H82E0
規格 Size
200ug
品牌 Brand
ACROBiosystems
Species
Human
Conjugate
Precision Avi
Expression System
HEK293
Tag
Avi Tag 、 His Tag

Description




Source : 


Biotinylated Human EMMPRIN, Avitag,His Tag (CD7-H82E0) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - His 205 (Accession # P35613-2).


 

Molecule : EMMPRIN


 

Synonyms : Basigin,BSG,5F7,CD147,EMMPRIN,M6,OK,TCSF


 

Format : Powder


 

Category : MABSol® Biotin Labeled Proteins


 

Accession : NP_940991.1


 

Storage : -20℃


 

Shipping condition : Powder,RT


 

Molecular Weight : 22.8 kDa


 

Characteristics :


This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 22.8 kDa. The protein migrates as 30-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.


 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.


 

Buffer : PBS, pH7.4


 

Description :


CD147 is also known as Basigin (BSG), or extracellular matrix metalloproteinase inducer (EMMPRIN). The human basigin protein contains 269 amino acids that form two heavily glycosylated C2 type immunoglobulin-like domains at the N-terminal extracellular portion. A second form of basigin has also been characterized that contains one additional immunoglobulin-like domain in its extracellular portion. As members of the immunoglobulin superfamily play fundamental roles in intercellular recognition involved in various immunologic phenomena, differentiation, and development, basigin is thought also to play a role in intercellular recognition and regulate several distinct functions, such as spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes. Basigin is a type I integral membrane receptor that has many ligands, including the cyclophilin (CyP) proteins Cyp-A and CyP-B and certain integrins.


 

References :


(1) Kasinrerk W, , et al.,1992, J Immunol 149 (3): 847–54.
(2) Yurchenko V, et al., 2006, Immunology 117 (3): 301–9.
(3) Kanekura T, et al., 2002, Int. J. Cancer 99 (4): 520–8.
(4) Hakuma, N. et al., 2007, Oncology. 72 : 197-204.





詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢